File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Primary refractory multiple myeloma: a real-world experience with 85 cases

TitlePrimary refractory multiple myeloma: a real-world experience with 85 cases
Authors
KeywordsDouble-refractory multiple myeloma
prognosis
treatment response
survival
Issue Date2020
PublisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal
Citation
Leukemia and Lymphoma, 2020, v. 61 n. 12, p. 2868-2875 How to Cite?
AbstractThis study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.
Persistent Identifierhttp://hdl.handle.net/10722/307678
ISSN
2023 Impact Factor: 2.2
2023 SCImago Journal Rankings: 0.790
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorJurczyszyn, A-
dc.contributor.authorWaszczuk-Gajda, A-
dc.contributor.authorCastillo, JJ-
dc.contributor.authorKrawczyk, K-
dc.contributor.authorStork, M-
dc.contributor.authorPour, L-
dc.contributor.authorUsnarska-Zubkiewicz, L-
dc.contributor.authorPotoczek, S-
dc.contributor.authorHus, I-
dc.contributor.authorDavila Valls, J-
dc.contributor.authorHari, P-
dc.contributor.authorChhabra, S-
dc.contributor.authorGentile, M-
dc.contributor.authorMikala, G-
dc.contributor.authorVarga, G-
dc.contributor.authorChim, CS-
dc.contributor.authorFiala, M-
dc.contributor.authorVij, R-
dc.contributor.authorSchutz, N-
dc.contributor.authorRodzaj, M-
dc.contributor.authorPorowska, A-
dc.contributor.authorVesole, DH-
dc.contributor.authorDruzd-Sitek, A-
dc.contributor.authorWalewski, J-
dc.contributor.authorNooka, AK-
dc.date.accessioned2021-11-12T13:36:12Z-
dc.date.available2021-11-12T13:36:12Z-
dc.date.issued2020-
dc.identifier.citationLeukemia and Lymphoma, 2020, v. 61 n. 12, p. 2868-2875-
dc.identifier.issn1042-8194-
dc.identifier.urihttp://hdl.handle.net/10722/307678-
dc.description.abstractThis study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.-
dc.languageeng-
dc.publisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal-
dc.relation.ispartofLeukemia and Lymphoma-
dc.rightsAccepted Manuscript (AM) i.e. Postprint This is an Accepted Manuscript of an article published by Taylor & Francis in [JOURNAL TITLE] on [date of publication], available online: http://www.tandfonline.com/[Article DOI].-
dc.subjectDouble-refractory multiple myeloma-
dc.subjectprognosis-
dc.subjecttreatment response-
dc.subjectsurvival-
dc.titlePrimary refractory multiple myeloma: a real-world experience with 85 cases-
dc.typeArticle-
dc.identifier.emailChim, CS: jcschim@HKUCC-COM.hku.hk-
dc.identifier.authorityChim, CS=rp00408-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/10428194.2020.1788014-
dc.identifier.pmid32623944-
dc.identifier.scopuseid_2-s2.0-85087612188-
dc.identifier.hkuros329783-
dc.identifier.volume61-
dc.identifier.issue12-
dc.identifier.spage2868-
dc.identifier.epage2875-
dc.identifier.isiWOS:000546279800001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats